DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation

Completed

Conditions: Chronic Lymphocytic Leukemia (CLL)
Cancer

Interventions: Drug: Venetoclax

First Posted Date: 2019-03-14

Last Posted Date: 2023-09-01

Lead Sponsor: AbbVie

Target Recruit Count: 71

Registration Number: NCT03873857

Locations: 🇷🇺
Clinical Medico-Sanitary Unit #1 /ID# 212364, Perm, Russian Federation
🇷🇺
Republican Hospital #1 - National Center of Medicine of Sakha (Yakutia) /ID# 212371, Yakutsk, Russian Federation
🇷🇺
Russian Research Institute of Hematology and Transfusiology of the FMBA /ID# 212372, Sankt-Peterburg, Russian Federation

and more 17 locations

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Placebo solution for risankizumab
Drug: Risankizumab

First Posted Date: 2019-03-14

Last Posted Date: 2021-03-16

Lead Sponsor: AbbVie

Target Recruit Count: 157

Registration Number: NCT03875482

Locations: 🇺🇸
Anaheim Clinical Trials LLC /ID# 212559, Anaheim, California, United States
🇺🇸
Skin Laser and Surgery Specialists of NY and NJ /ID# 210208, Hackensack, New Jersey, United States
🇺🇸
Arlington Research Center, Inc /ID# 210344, Arlington, Texas, United States

and more 40 locations

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Risankizumab
Device: Autoinjector

First Posted Date: 2019-03-14

Last Posted Date: 2021-05-11

Lead Sponsor: AbbVie

Target Recruit Count: 108

Registration Number: NCT03875508

Locations: 🇺🇸
Tien Q Nguyen MD, Inc /ID# 210775, Fountain Valley, California, United States
🇺🇸
Advanced Research Associates /ID# 210634, Glendale, Arizona, United States
🇺🇸
Bakersfield Derma & Skin Cance /ID# 210773, Bakersfield, California, United States

and more 23 locations

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia
T-cell Prolymphocytic Leukemia (T-PLL)
Cancer

Interventions: Drug: Venetoclax
Drug: Ibrutinib

First Posted Date: 2019-03-13

Last Posted Date: 2022-12-19

Lead Sponsor: AbbVie

Target Recruit Count: 14

Registration Number: NCT03873493

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center /ID# 207746, Houston, Texas, United States
🇬🇧
Oxford University Hospitals NHS Foundation Trust /ID# 211264, Oxford, Oxfordshire, United Kingdom
🇳🇱
Maxima Medisch Centrum /ID# 207989, Eindhoven, Netherlands

and more 12 locations

Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation

Completed

Conditions: Chronic Hepatitis C (CHC)

First Posted Date: 2019-03-08

Last Posted Date: 2021-08-30

Lead Sponsor: AbbVie

Target Recruit Count: 161

Registration Number: NCT03868163

Locations: 🇷🇺
LLC Medical Company Hepatolog /ID# 212384, Samara, Samarskaya Oblast, Russian Federation
🇷🇺
A. F. Agafonov Republican Clin /ID# 212381, Kazan, Tatarstan, Respublika, Russian Federation
🇷🇺
Clinical Inf. Dis Hospital 1 /ID# 217033, Novosibirsk, Russian Federation

and more 6 locations

A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)

Phase 4

Terminated

Conditions: Exocrine Pancreatic Insufficiency (EPI)

Interventions: Drug: Pancrelipase
Drug: Placebo

First Posted Date: 2019-03-01

Last Posted Date: 2023-06-05

Lead Sponsor: AbbVie

Target Recruit Count: 1

Registration Number: NCT03859869

Locations: 🇺🇸
Fox Chase Cancer Center /ID# 202288, Philadelphia, Pennsylvania, United States
🇺🇸
NorthShore University HealthSystem /ID# 209026, Evanston, Illinois, United States
🇺🇸
East Carolina University /ID# 206661, Greenville, North Carolina, United States

and more 30 locations

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Active, not recruiting

Conditions: Open-Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost (SR)

First Posted Date: 2019-02-22

Last Posted Date: 2024-02-13

Lead Sponsor: AbbVie

Target Recruit Count: 515

Registration Number: NCT03850782

Locations: 🇺🇸
Fraser Eye Center /ID# 235790, Fraser, Michigan, United States
🇺🇸
AMA Eyes Research Institute /ID# 235542, Marysville, Ohio, United States
🇧🇬
MHAT Hadzhi Dimitar /ID# 238248, Sliven, Bulgaria

and more 105 locations

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Multiple Myeloma
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia
Cancer

Interventions: Drug: Venetoclax

First Posted Date: 2019-02-18

Last Posted Date: 2025-05-06

Lead Sponsor: AbbVie

Target Recruit Count: 165

Registration Number: NCT03844048

Locations: 🇬🇧
Blackpool Teaching Hospitals NHS Foundation Trust /ID# 225163, Blackpool, United Kingdom
🇬🇧
Clatterbridge Cancer Centre - Liverpool /ID# 218736, Liverpool, United Kingdom
🇬🇧
King's College Hospital NHS Foundation Trust /ID# 218735, London, United Kingdom

and more 53 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Phase 2

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Placebo for ABBV-3373
Drug: ABBV-3373
Drug: Adalimumab
Drug: Placebo for adalimumab

First Posted Date: 2019-01-30

Last Posted Date: 2021-07-19

Lead Sponsor: AbbVie

Target Recruit Count: 48

Registration Number: NCT03823391

Locations: 🇺🇸
PCCR Solution /ID# 215457, Colleyville, Texas, United States
🇺🇸
C.V. Mehta MD, Med Corporation /ID# 213068, Hemet, California, United States
🇺🇸
Robin K. Dore MD, Inc /ID# 213045, Tustin, California, United States

and more 27 locations

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

Phase 2

Terminated

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Elsubrutinib
Drug: Placebo for upadacitinib
Drug: Placebo for elsubrutinib
Drug: Upadacitinib

First Posted Date: 2019-01-30

Last Posted Date: 2021-09-16

Lead Sponsor: AbbVie

Target Recruit Count: 97

Registration Number: NCT03823378

Locations: 🇵🇱
ClinicMed Daniluk, Nowak Sp.j. /ID# 212578, Białystok, Podlaskie, Poland
🇭🇺
CMED Rehabilitacios es Diagnosztikai Kozpont /ID# 208188, Szekesfehervar, Hungary
🇵🇱
NBR Polska /ID# 209904, Warsaw, Mazowieckie, Poland

and more 27 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy